** Shares of vaccine maker Moderna MRNA.O fall 2.7% to $27

** Moderna looking for partners to conduct late-stage studies on its experimental vaccines targeting Epstein-Barr virus, varicella zoster virus and genital herpes, the company said at an industry conference late on Wednesday

** MRNA said it will not take the experimental vaccines to late-stage trials on its own

** Including session's move, stock down 35% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))